Global pioneer in the pharmaceutical cannabis sector with exclusive market access seeks strategic equity partner

This GMP-licensed Jamaican cannabis facility is looking for $10M to expand in the U.S. and Brazil. Backed by a 5-year Brazil supply deal and DEA import permits, it projects $10.8M revenue in 2025 and $36.5M in 2026. With global export, white-label potential, and major upside as U.S. laws evolve, it’s a strong growth opportunity.

• Leading Jamaican pharmaceutical cannabis manufacturer, uniquely positioned to capitalize on the rapidly growing US and Brazilian markets by offering the highest level of quality, medical-grade products, and regulatory compliance that surpass traditional medical cannabis offering

• Company has an exclusive 5-year supply agreement in Brazil to provide pharmaceutical THC into a state-owned pharma network, serving over 40 million people with 100% insurance reimbursement.

• Positioned for direct-to-consumer and direct-to-pharmacy distribution in the US, aligning with the DEA’s expected rescheduling of THC to Schedule III in 2025.

• Over 100 pharmaceutical THC shipments have been successfully exported to Brazil and the US under DEA and ANVISA import permits.

• Established strategic joint venture in Brazil with a leading distributor grants access to 13,000 pharmacies and 300,000 food and beverage points of sale across all 27 Brazilian states.

• EBITDA is forecasted to be positive by Q4 2025, with projected revenues of $10.8M for 2025 and $36.5M by 2026, driven by long-term contracts.

• Proven leadership team, consisting of seasoned executives with expertise in pharmaceuticals, consumer goods, and cannabis, including early pioneers of leading cannabis firms.

• The GMP-certified facility allows for white-label manufacturing for US brands seeking compliant, pharmaceutical-grade THC for legal distribution across all 50 states post-rescheduling.

• Company has invested $10M USD to date, supported by a licensed and GMP-certified pharmaceutical manufacturing facility located in a Free Trade Zone.

• The 5-year DCF valuation stands at $138M, representing significant investment upside based on projected sales, market expansion, and regulatory tailwinds.

• Seeking US equity financing to scale into the prescription cannabinoids market in the US and Brazil, with additional countries and prescription psychedelics (both psilocybin and ibogaine) as incremental upside.

• Pharmaceutical Cannabis Market Growth and Strategic Advantages:

• The pharmaceutical cannabis market is rapidly growing, with Brazil’s market expected to reach $14.2B by 2030 (71.4% CAGR) and the US market projected to hit $19.7B by 2030 (65.3% CAGR).

• Low-cost jurisdiction, operations in Jamaica's Special Economic Zone provide duty-free export advantages to the US, Brazil, UK, EU, and other global markets. Note: duty-free trade with only 12.5% corporate tax.

• US market is seen as a "free call option," with valuation projections excluding potential US revenues, adding upside for investors after the DEA reschedules THC.